Mid-day market update: Immunomedics jumps following acquisition news; Mallinckrodt shares slide
|Midway through trading Monday, the Dow traded up 1.38% to 28046.83 while the NASDAQ rose 2.41% to 11,114.71. The S&P also rose, gaining 1.73% to 3,398.74.
The U.S. has the highest number of coronavirus cases and deaths in the world, reporting a total of 6,520,600 cases with around 194,080 deaths. India confirmed a total of at least 4,846,420 confirmed cases and 79,720 deaths, while Brazil reported over 4,330,450 COVID-19 cases with 131,620 deaths. In total, there were at least 29,019,630 cases of COVID-19 worldwide with over 924,460 deaths, according to data compiled by Johns Hopkins University.
Leading and Lagging Sectors
Information technology shares climbed 2.5% on Monday. Meanwhile, top gainers in the sector included Priority Technology Holdings, Inc. PRTH 14.48%, up 15%, and Kingsoft Cloud Holdings Limited KC 13.18%, up 15%.
In trading on Monday, energy shares rose by just 0.6%.
Top Headline
NVIDIA Corporation NVDA 6.22% announced plans to acquire British chipmaker Arm Ltd from SoftBank Group’s Vision Fund, in a deal valued at $40 billion.
Under the deal, the Santa Clara, California-based company will fund the purchase of all of Arm’s shares in $12 billion cash and $21.5 billion in stock. $2 billion in cash would be payable at signing of the agreement, Nvidia said in a statement.
Equities Trading UP
Immunomedics, Inc. IMMU 100.21% shares shot up 100% to $84.51. Gilead Sciences, Inc. GILD 1.73% announced plans to acquire Immunomedics in a deal at $21 billion.
Shares of Cassava Sciences, Inc. SAVA 88.55% got a boost, shooting 88% to $6.25 after the company announced results for a Phase 2b clinical study of Sumifilam in patients with Alzheimer's disease showed statistically significant improvements in biomarkers compared to placebo.
Scientific Games Corporation SGMS 45.49% shares were also up, gaining 45% to $27.60 after the company announced new institutional investors would take a stake in the company at $28 per share. Shares are being purchased from current shareholders.
Equities Trading DOWN
Kala Pharmaceuticals, Inc. KALA 10.6% shares tumbled 12% to $7.74. Jefferies downgraded Kala Pharmaceuticals from Buy to Hold and lowered the price target from $21 to $10.
Shares of ClearOne, Inc. CLRO 7.02% were down 7% to $2.27 after the company reported a $5.3 million registered direct offering priced at-the-market under Nasdaq rules.
Mallinckrodt plc MNK 6.64% was down, falling 6% to $1.1250 after the FDA denied the company's new drug application to treat kidney failure.
Commodities
In commodity news, oil traded down 0.4% to $37.19, while gold traded up 1.1% to $1,969.90.
Silver traded up 2.2% Monday to $27.45, while copper rose 1.1% to $3.073.
Euro zone
European shares were mixed today. The eurozone’s STOXX 600 rose 0.15%, the Spanish Ibex Index rose 0.11%, while Italy’s FTSE MIB Index fell 0.14%. Meanwhile, the German DAX 30 declined 0.07%, French CAC 40 rose 0.35% and London’s FTSE 100 fell 0.1%.
Eurozone reported that its industrial production climbed better-than-expected by 4.1% in July, versus analysts’ estimates of a 4% increase.
Economics
On the economics calendar Monday, there is no important data due out.
Information on these pages contains forward-looking statements that involve risks and uncertainties. Markets and instruments profiled on this page are for informational purposes only and should not in any way come across as a recommendation to buy or sell in these assets. You should do your own thorough research before making any investment decisions. FXStreet does not in any way guarantee that this information is free from mistakes, errors, or material misstatements. It also does not guarantee that this information is of a timely nature. Investing in Open Markets involves a great deal of risk, including the loss of all or a portion of your investment, as well as emotional distress. All risks, losses and costs associated with investing, including total loss of principal, are your responsibility. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of FXStreet nor its advertisers.